Georgia Bio Executive Committee

Patty Fritz
Chair, Georgia Bio
Vice President, U.S. Corporate Affairs, UCB, Inc.

Patty Fritz is vice president, U.S. Corporate Affairs for UCB, Inc, overseeing policy, government affairs, advocacy, patient engagement, communications and UCBCares®. Patty leads efforts to create value for patients and their families through strategic engagement and positively influencing the healthcare environment and policy landscape. 

At UCB, everything we do starts with one simple question: “how will this create value for people living with severe diseases?” In her Corporate Affairs role, Patty finds opportunities to better understand the unique needs of patients, so we can continue delivering value. She is a champion of innovative projects to spotlight the importance of access and care for people living with severe diseases. Recent efforts Patty has led include collaborations with the VA Epilepsy Centers of Excellence, PatientsLikeMe®, Emory University, Georgia Tech and IBM.

Having been with UCB for more than 20 years, Patty has made a significant impact in different leadership roles including Regulatory Affairs, Operational Excellence, Government Affairs and Policy. She managed teams and inspired colleagues as UCB transformed from a primary care company to a specialty biopharma pharmaceutical leader focused on severe diseases. Patty led the regulatory efforts for UCB’s first product filing - Keppra® (levetiracetam) - and oversaw the FDA approval process for many of UCB’s other products including Lortab™ (hydrocodone), Xyzal® (levocetirizine), Cimzia® (certolizumab pegol) and Vimpat® (lacosamide). She also championed and was a driving force behind the establishment of UCB’s Women in Leadership initiative. 

Outside of UCB, Patty serves as chair of the board of directors for Georgia Bio and as a member of The Carter Center Board of Councilors. 

Patty holds a master’s degree in health care policy and administration from Mercer University (Atlanta, Ga.) and a Bachelor of Science degree in management and technology from the University of Maryland (Laurel, Md.). Patty is also a graduate of Summers County School of Nursing (Hinton, W.Va.).

H. Lee Herron, DVM
Vice Chair, Georgia Bio
Vice President, Venture Development, Georgia Research Alliance (GRA)

Dr. Lee Herron joined the Georgia Research Alliance in 2008 to direct its venture development program, which has launched 180 companies and attracted more than $1 billion in equity investment.

GRA supports universities in forming new companies around their discoveries, providing seed funds and access to experienced mentoring and expert consulting. As vice president of venture development, Lee does everything from reviewing business proposals to meeting with faculty scientists. He often walks university halls and drops by labs, gaining an insider’s perspective on the newest innovations that could lead to a new company.

Lee helps GRA portfolio companies prepare a strong pitch to investors. Drawing on his own 17 years of entrepreneurial experience, he ensures that companies adopt a sound business strategy and operational plans. As Lee explains, it’s not enough to just have a brilliant idea. “Successful entrepreneurs must be comprehensive in their understanding of what questions to ask.” Lee guides faculty and entrepreneurs in figuring out the right questions, a role that has earned him the nickname “Start-up Sherpa.” 

Previously, Lee managed the biosciences division of Georgia Tech’s Advanced Technology Development Center (ATDC), advising early stage life science companies. In his earlier career, he founded SeaLite Sciences, Inc., a company that developed and commercialized diagnostic products and molecular biology reagents derived from a light-emitting protein found in jellyfish. He was also a founding team member of three other bioscience companies: Biopool International, Inc., CytRx Corporation, and Theragenics Corporation. Lee also worked with German biotech company BRAHMS AG to establish its North American operations.

Today, Lee serves on the boards of Georgia Bio and Southeast Bio, and is a special advisor to the Executive Committee of Georgia’s Bio/Med Investor Network. Lee serves on numerous advisory committees, and he was Chairman of the 2017 Georgia Bio Innovation Summit.

Lee holds a Doctor of Veterinary Medicine degree from The University of Georgia. He also studied experimental pathology at Emory University.

Jay Yadav, M.D.
Immediate Past Chair, Georgia Bio
Founder & CEO, MiRus LLC

Jay S. Yadav, M.D., is the Founder and CEO of MiRus, LLC, an orthopaedic and spine company. He was the founder of CardioMEMS (acquired by St. Jude Medical), Angioguard (acquired by JNJ) and initial investor and director of SMART Therapeutics (acquired by Boston Scientific). Dr. Yadav is a director of several private life sciences and technology companies. He is a Director of Georgia Bio, the Global Center for Medical Innovation (GCMI), the Bio/Med Investor Network, the Southeast Medical Device Association (SEMDA) and Beacon College. He is on the Entrepreneurship Advisory Board of the Yale School of Management.

Dr. Yadav has authored two books, over two hundred publications, and holds over forty patents. He has received numerous honors including the American Heart Association Top Ten Scientific Advances for 2003, Ellis Island Medal of Honor for 2004, Southeast Medical Device Association Entrepreneur of the Year Award for 2010, Phoenix Award for Medical Devices 2011, Association of Telecom Professionals Award 2011, Ernst and Young Entrepreneur of the Year for Healthcare (Southern Region) for 2011, Association for Corporate Growth Deal of the Year 2014 and Georgia Bio Deal of the Year 2014.

Heather Mullins, CPA
Partner, Frazier & Deeter

Heather Mullins is an Audit Partner in the Assurance and Advisory Services Practice of Frazier & Deeter. Prior to joining Frazier & Deeter in 2005, Heather spent five years in the audit practice for one of the Big Four accounting firms where she served large public companies and private companies in the middle market. Heather brings over 22 years of experience in public accounting. Her effective problem solving, leadership and communication skills strengthen her ability to provide insights and help her clients reach sound and practical conclusions.

Heather has worked with a variety of institutions, assisting clients with development of policies and procedures and internal controls over financial reporting, as well as performing and managing financial statement reviews and audits and other attestation engagements. Heather works mainly with middle market companies in the private sector, heading up Frazier & Deeter’s Healthcare Practice, as well as focusing on manufacturing and distribution companies, service providers, financial services companies and technology companies.

Heather works closely with Frazier & Deeter’s audit methodology to ensure quality and consistency of procedures throughout the assurance practice. In addition to leading the Healthcare Practice, Heather is a member of the firm’s Technology Industry Group, Manufacturing & Distribution Industry Group and Service Industry Group.

William L. Warren 
Corporate Counsel
Partner - IP Practice Group Leader, Eversheds Sutherland LLP

Bill Warren advises clients on strategic intellectual property issues primarily in the life sciences sector, but also in a number of other industries. The majority of his practice focuses on patents related to biotechnology, medical device and pharmaceutical inventions. Bill prosecutes patents, counsels clients on patent validity and infringement issues and prepares product clearance opinions and development strategies. He also negotiates technology transfer licensing agreements and conducts intellectual property due diligence. Bill protects patents, trademarks and copyrights and, when necessary, participates in litigating intellectual property issues. Bill currently leads Sutherland’s Intellectual Property Practice Group and is chair of the firm’s biotechnology & life sciences team. 

Russell Medford, MD, Ph.D.
Governance, Nominating & Compensation Committee Chair
Managing Partner, Salutramed Group

Russell M. Medford, MD, PhD, Managing Partner is a senior biotechnology executive with extensive private and public company experience as Chief Executive Officer and Board member of multiple biotechnology and other health related companies, organizations and research institutes. From 1995 to 2009, Dr. Medford served as co-founder, President, CEO and Director of publicly-held AtheroGenics, Inc (Nasdaq: AGIX) and from 2009 to 2012 CEO and Chairman of Salutria Pharmaceuticals, LLC. He was a founding Board Director of publicly-held Inhibitex, Inc. (Nasdaq: INHX) until it was acquired by Bristol-Myers-Squibb in 2012 for $2.5 billion. He has had extensive experience leading companies and organizations engaged in comprehensive therapeutic drug research and development, developing multiple, novel, first-in-man clinical candidates for the treatment of cardiovascular disease, diabetes and arthritis, conducted multiple phase I, II and III clinical studies involving over 400 clinical trial sites in 12 countries, including the US, UK, Canada, South Africa, India, Russia, Eastern Europe and India involving more than 7000 patients, executed multiple strategic partnerships with major pharmaceutical companies including Schering-Plough, Fujisawa and AstraZeneca, as well as building a commercial-scale, manufacturing plant for lead, small-molecule pharmaceutical agents. He has extensive experience in both the private and public financial markets including initial public offerings (IPO) raising over $500 million for corporate, clinical development and research programs. He has served on multiple private company Boards including Transcardiac Therapeutics, Inc., Somatocor, Inc. and EmTech Bio. He is a board-certified physician, an inaugural Fellow of the Council on Basic Cardiovascular Sciences of the American Heart Association, a member of the executive committee and former Chairman of GeorgiaBio, a member of Biotechnology Industry Organization’s (BIO) Board of Directors, Emerging Companies Section Governing Board and Health Science Governing Board, Co-Chairman of BIO’s Bioethics Committee and served as Chairman of the BIO's 2009 International Convention Steering Committee. Dr. Medford is a past member of the Advisory Council of the National Heart, Lung and Blood Institute and currently serves on the Board of Trustees of the National Health Museum and Chairman of the External Advisory Board for the Petit Institute of Bioscience and Bioengineering of the Georgia Institute of Technology. He has received numerous awards including the Ernst and Young Entrepreneur of the Year Award (Southeast), the Biomedical Industry Growth Award (Georgia Bio), CATALYST Magazine's Top 50 Entrepreneurs and the SCRIPP Best Partnership Alliance (London). Dr. Medford also serves as Chairman of Artetude Gallery, Inc., a private, North Carolina contemporary fine art company based in Asheville. Dr. Medford was an Associate Professor of Medicine, Director of Molecular Cardiology and Adjunct Clinical Professor of Medicine at the Emory University School of Medicine where he founded Atherogenics, Inc. He received a B.A. from Cornell University, and a M.D. with Distinction and a Ph.D. in Molecular and Cell Biology from the Albert Einstein College of Medicine, completing his residency and cardiology fellowship at Harvard’s Beth Israel and Brigham and Women’s Hospitals where he also served on the faculty of Medicine. He publishes widely and holds over 16 U.S. and international patents.

Kallarin Mackey
Director of State Affairs, Government and Community Affairs
Emory University

Kallarin Mackey is the Director of State Affairs for Emory University, where she leads advocacy efforts on behalf of the University and healthcare system before state legislative, executive and regulatory officials.

Before joining Emory, she worked at the Georgia Hospital Association in government relations as Director of Public Policy. Prior to moving to the private sector, Kallarin spent three years as a liaison between state government health agencies and the legislature. During her time at the Georgia Department of Community Health and Georgia Department of Public Health, she gained valuable experience working directly with healthcare payers including Medicaid, State Health Benefit Plan and private insurers, as well as working across various public health programs.

She first began building her experience in the Georgia General Assembly while working in the Georgia Senate Press Office, where she managed the press and media needs of Georgia’s state Senators.

Kallarin graduated from Brenau University in Gainesville, Georgia with a B.A. in Public Relations and is currently pursuing her M.B.A at Emory University’s Goizueta Business School.  She lives in Brookhaven with her husband, Josh.

Danica A. Dilligard
Finance and Audit Committee Chair
Partner | South East Region – Health and Life Sciences Assurance Leader
Ernst & Young LLP

Danica A. Dilligard is an audit partner based in the Ernst & Young Atlanta office.  Danica has over 21 years combined experience serving global and domestic public and private companies in the Life Sciences and Technology industries. 

Ms. Dilligard has extensive experience with multinational and multi-location audits including acquisitions and divestitures, product acquisitions, product collaboration arrangements, and spin-off transactions which includes the integration and separation accounting and auditing considerations around such transactions across several industries. In addition to her client responsibilities, Danica has assumed the role of leading inspections in the Latin America and Israel markets for the Americas Professional Practice Quality and Risk Management group. Her private experience includes being the Director of Financial Reporting and Divisional Controller for a large publishing company. 

Danica leverages her experience from these roles to ensure she brings the firms best resources to her clients to address their critical business objectives.

Danica is a certified public accountant in New York, New Jersey and Atlanta and is a member of the New Jersey State Society of Public Accountants, ALPFA and National Association of Black Accounts.  Danica has a Bachelors in Business Administration – Accounting from Bernard Baruch College of New York City.

Tiffany Wilson
2018 Georgia Bio Innovation Summit Chair

Tiffany has spent more than 15 years bringing innovative medical technology from benchtop to bedside. She joined GCMI in 2011 to lead its startup phase, establishing overall strategic vision, building strategic relationships and bringing together key stakeholders of the medical device ecosystem. Her strong background in medical devices, commitment to fostering innovation and understanding of business strategies have propelled her into a leadership role in the Southeast and brought her into the national spotlight. Wilson joined GCMI from Scientific Intake, where she served as the Vice President of Business Development and Strategy, evaluating marketing and distribution opportunities and driving product development projects for the global obesity market. Prior to Scientific Intake, she was Vice President of Corporate Strategy and Finance at ACell, Inc., a regenerative medicine and tissue engineering company based in Columbia, Maryland. At ACell, she led a broad range of initiatives including corporate finance, investor relations, strategic and operational planning, business development, regulatory, and reimbursement. Tiffany serves as Past-President of the Board of the Southeast Medical Device Association (SEMDA), Founding Member of Medtech Women @ SEMDA, Chair of the T3 Labs Advisory Board, and the Georgia Bio Board of Directors. She is a Member of the National Advisory Council on Innovation and Entrepreneurship (NACIE) at the U.S. Department of Commerce. She led the Sponsorship Committee of the 2013 SEMDA Conference and has served as the Co-Chair of the Medical Device Subcommittee of the Metro Atlanta Chamber Bioscience Leadership Council. In 2015 Tiffany received the prestigious Georgia Bio Community Award and in 2017 was presented with the Industry Growth Award, the highest honor bestowed each year by Georgia Bio.  She was recently recognized by Inc. Magazine as one of “17 Inspiring Women to Watch in 2017” and one of Becker Hospital Review’s “110 Women in Medtech to Know in 2017”.

Philip Gibson, Ph.D.
2019-2020 Georgia BioEd Institute Chair
Director, Georgia Bioscience Training Center at QuickStart

Philip G. Gibson, Ph.D., is the Director of the Georgia BioScience Training Center for Georgia Quick Start. The training center is designed to train employees in life science industries. It is a state-of-the-art training center capable of delivering biomanufacturing training on large scale equipment typical to the biomanufacturing industry. Additionally, quality laboratory, quality assurance, warehousing, and maintenance training are all delivered at the center. The center utilizes wireless and paperless-based instruction with hands-on focused curriculum.

Dr. Gibson was an instructor at Gwinnett Technical College from 1989 to 2014. He taught a wide range of topics including; biochemistry, nucleic acids, proteins, laboratory methods, instrumental methods of analysis, laboratory safety, biotechnology seminar, and regulatory compliance. Students relied upon Dr. Gibson for advisement, career counseling and job placement.

Dr. Gibson worked collaboratively through Gwinnett Technical College and Athens Technical College to develop educational opportunities for students interested in science and math-based careers. A 1.99 million dollar Community-Based Job Training Grant (CBJTG) from the US Department of Labor awarded in December of 2006 funded several initiatives relating to bioscience. The Bioscience Program at Gwinnett Technical College was created through the CBJTG. This program was developed and grew under Dr. Gibson’s direction. During this period, the State of Georgia developed regional, industry-focused grants which included math and science educational initiatives. Dr. Gibson participated in the delivery of teacher training and development of curriculum under portions of 0.9 million dollars in State grant funding. CLICK HERE TO KEEP READING PHIL’S BIO.